BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30753823)

  • 1. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.
    Carugo A; Minelli R; Sapio L; Soeung M; Carbone F; Robinson FS; Tepper J; Chen Z; Lovisa S; Svelto M; Amin S; Srinivasan S; Del Poggetto E; Loponte S; Puca F; Dey P; Malouf GG; Su X; Li L; Lopez-Terrada D; Rakheja D; Lazar AJ; Netto GJ; Rao P; Sgambato A; Maitra A; Tripathi DN; Walker CL; Karam JA; Heffernan TP; Viale A; Roberts CWM; Msaouel P; Tannir NM; Draetta GF; Genovese G
    Cancer Cell; 2019 Feb; 35(2):204-220.e9. PubMed ID: 30753823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
    Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
    Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
    Pawel BR
    Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
    Kohashi K; Oda Y
    Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
    Darr J; Klochendler A; Isaac S; Eden A
    Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors.
    Xue Y; Zhu X; Meehan B; Venneti S; Martinez D; Morin G; Maïga RI; Chen H; Papadakis AI; Johnson RM; O'Sullivan MJ; Erdreich-Epstein A; Gotlieb WH; Park M; Judkins AR; Pelletier J; Foulkes WD; Rak J; Huang S
    J Pathol; 2020 Sep; 252(1):77-87. PubMed ID: 32558936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MYC by the SMARCB1 tumor suppressor.
    Weissmiller AM; Wang J; Lorey SL; Howard GC; Martinez E; Liu Q; Tansey WP
    Nat Commun; 2019 May; 10(1):2014. PubMed ID: 31043611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
    Darr J; Klochendler A; Isaac S; Geiger T; Eden A
    Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
    Kuwahara Y; Wei D; Durand J; Weissman BE
    Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.
    Kia SK; Gorski MM; Giannakopoulos S; Verrijzer CP
    Mol Cell Biol; 2008 May; 28(10):3457-64. PubMed ID: 18332116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development.
    Vitte J; Gao F; Coppola G; Judkins AR; Giovannini M
    Nat Commun; 2017 Aug; 8(1):300. PubMed ID: 28824165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.
    Oruetxebarria I; Venturini F; Kekarainen T; Houweling A; Zuijderduijn LM; Mohd-Sarip A; Vries RG; Hoeben RC; Verrijzer CP
    J Biol Chem; 2004 Jan; 279(5):3807-16. PubMed ID: 14604992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
    Kim KH; Roberts CW
    Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
    Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
    Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
    Li T; Wang J; Liu P; Chi J; Yan H; Lei L; Li Z; Yang B; Wang X
    Oncotarget; 2017 Jul; 8(29):47269-47283. PubMed ID: 28521298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.
    DelBove J; Kuwahara Y; Mora-Blanco EL; Godfrey V; Funkhouser WK; Fletcher CD; Van Dyke T; Roberts CW; Weissman BE
    Mol Carcinog; 2009 Dec; 48(12):1139-48. PubMed ID: 19676100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.
    Venneti S; Le P; Martinez D; Eaton KW; Shyam N; Jordan-Sciutto KL; Pawel B; Biegel JA; Judkins AR
    J Neuropathol Exp Neurol; 2011 Jul; 70(7):596-609. PubMed ID: 21666498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapeutic targets for the treatment of malignant rhabdoid tumors.
    Nemes K; Frühwald MC
    Expert Opin Ther Targets; 2018 Apr; 22(4):365-379. PubMed ID: 29528755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
    Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
    Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.